Lv3
220 积分 2022-08-03 加入
Mechanism of uptake and toxicity of a BCMA antibody drug conjugate with a MMAF payload by nonantigen expressing cells
1天前
待确认
Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes
2天前
求助中
CAR T cell therapies for patients with multiple myeloma
2天前
已完结
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
3天前
已完结
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
7天前
已完结
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
8天前
已关闭
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
9天前
已关闭
Minimal Residual Disease in Mantle Cell Lymphoma
11天前
已完结
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma
11天前
已完结
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma
14天前
已完结
皖公网安备34019202002308
